Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
28 mars 2019 16h00 HE
|
Capricor Therapeutics, Inc.
Plan to Report Interim Data from HOPE-2 Clinical Trial in Early Q3 To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, March 28, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present Corporate Overview and Poster at Action Duchenne International Conference
08 nov. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Research Found Exosomes Increased Exercise Capabilities and Muscle Activity in a Mouse Model of Duchenne Muscular Dystrophy LOS ANGELES, Nov. 08, 2018 (GLOBE NEWSWIRE) -- During the Action...
Capricor Therapeutics to Participate in Upcoming Conferences
22 oct. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy Therapies LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc....
Capricor Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa
03 oct. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LA JOLLA, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) will provide a presentation at the 2018 Cell & Gene Meeting on the Mesa today on its cell therapy,...
Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
21 août 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, Aug. 21, 2018 (GLOBE NEWSWIRE) -- At the Gordon Research Conference on Extracellular Vesicles in Newry, Maine, Capricor Therapeutics (NASDAQ: CAPR) presented research findings on the...
Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
09 août 2018 16h00 HE
|
Capricor Therapeutics, Inc.
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology...
Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
17 juil. 2018 07h00 HE
|
Capricor Therapeutics, Inc.
LOS ANGELES, July 17, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR) today announced it has entered into an agreement with the U.S. Army Institute of Surgical Research (USAISR) to...
Exosome Diagnostics Achieves ISO 13485:2016 Certification
13 juin 2018 07h07 HE
|
Exosome Diagnostics
Waltham, MA, June 13, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced that it has achieved ISO 13485:2016 certification for their Munich location, upgraded from the ISO 13485:2003...
Exosome Diagnostics’ Second Prospective Validation Study of EPI to be Highlighted at American Urological Association (AUA) Annual Meeting Press Briefing in San Francisco, CA
17 mai 2018 12h47 HE
|
Exosome Diagnostics
Waltham, MA, May 17, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics’ novel urine-based prostate cancer liquid biopsy biomarker test, ExoDx™ Prostate(IntelliScore) or EPI, was selected out of 3000...
Exosome Diagnostics Presents Breakthrough Data Highlighting Tumor Derived RNA in Biofluids at the International Society for Extracellular Vesicles in Spain
15 mai 2018 09h52 HE
|
Exosome Diagnostics
Waltham, MA, May 15, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. received great interest from their presentations at the International Society for Extracellular Vesicles (ISEV) 2018 in...